Navigation Links
BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
Date:3/30/2009

xclusivity in the United States and ten years of market exclusivity in the E.U.

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. To learn more about PKU, please visit www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin to Present at the 4th Annual Citi Biotech Day
2. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
3. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
4. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
5. BioMarin to Present at the Piper Jaffray Healthcare Conference
6. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
7. BioMarin to Present at the Credit Suisse Healthcare Conference
8. BioMarin Announces Third Quarter 2008 Financial Results
9. BioMarin Corrects Information Included in Bloomberg Article
10. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
11. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014  Discovery Laboratories, ... has been awarded a Phase II Small Business ... $3.0 million from the National Institute of Allergy ... of Health (NIH) to support the development of ... a medical countermeasure to mitigate acute and chronic/late-phase ...
(Date:10/1/2014)... Oct. 1, 2014 Pfanstiehl has announced ... EP), manufactured in the USA ... long been recognized for playing a key role ... body of evidence that media supplementation with mannose ... protein glycosylation," according to Dr. Christopher Wilcox ...
(Date:10/1/2014)... 2014 In response to its ... address sales, training and consumer engagement challenges, ... mobile applications to turn their clients’ visions into ... customized mobile app creations, are now featured on ... partnership with Toyota, StudioPMG created a robust cross-platform ...
(Date:10/1/2014)... TeselaGen Biotechnology has received a ... their bioCAD/CAM software suite, which uses synthetic biology ... Business Innovation Research Phase II grant will be used ... from the Lawrence Berkeley National Laboratory. j5 was developed ... laboratory that develops alternative fuel technologies for the Department ...
Breaking Biology Technology:Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) announced today that it ... Equity Conference to be held August,18-19, 2008 at the ... of Access is scheduled to speak on Monday, August ... and will give a corporate overview and,discuss the Company,s ...
... Anthera Pharmaceuticals,Inc., a privately held biopharmaceutical company ... a $19 Million,equity financing. New investors Caxton ... HBM BioCapital (Cayman Islands) led the financing, ... Advantage Venture Partners (the,General Partner of Caxton ...
... MS, EDMONTON, Aug. 12 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced financial and ... 2008. BioMS Medical, in partnership with Eli Lilly ... for the treatment of MS,undergoing pivotal trials in ...
Cached Biology Technology:Access Pharmaceuticals to Present at the Noble Financial Equity Conference 2Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman 2Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman 3BioMS Medical Announces Second Quarter 2008 Results 2BioMS Medical Announces Second Quarter 2008 Results 3BioMS Medical Announces Second Quarter 2008 Results 4BioMS Medical Announces Second Quarter 2008 Results 5
(Date:9/30/2014)... of the environmental effects of moorland burning is published ... subject, with the aim of relieving tensions on both ... The EMBER (Effects of Moorland Burning on the Ecohydrology ... on moorland, which is practised predominantly to support red ... on peat hydrology, peat chemistry and physical properties, river ...
(Date:9/30/2014)... comprehensive assessment conducted by the Ocean Health Index ... 100 in overall health. In addition, for the ... the 15 ocean regions beyond national jurisdiction (high-seas ... healthy climate, safeguarding biodiversity and providing sustainable food ... the index, a partnership led by scientists from ...
(Date:9/30/2014)... The National Institutes of Health (NIH) awarded Lawrence ... develop an electrode array system that will enable ... through unprecedented resolution and scale. , LLNL,s grant-funded ... President Obama,s BRAIN (Brain Research through Advancing ... to revolutionize our understanding of the human mind ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2Rating the planet's oceans 2Rating the planet's oceans 3NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
... of modern-day birds took to the skies by gliding ... and legs, according to new research by a University ... journal Paleobiology, Department of Biological Sciences PhD student Nick ... taking off from the ground while running and shows ...
... role in mediating the outcome of competition between rival ... in the New World--or, on a much smaller ecological ... to competing bacteria. In a new study, researchers have ... with one another, and they have found that each ...
... directly comparing weight-loss outcomes in super-obese patients, researchers ... newer operation, the duodenal switch, produced substantially better ... gastric bypass. , In the October issue of ... the duodenal switch (DS) produced greater weight loss ...
Cached Biology News:Ancient birds flew on all-fours 2Different strategies underlie the ecology of microbial invasions 2For super-obese patients, duodenal switch beats gastric bypass 2For super-obese patients, duodenal switch beats gastric bypass 3
For testing the AQUA technique on your MS instruments....
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
...
Biology Products: